GenixPharmaceucticals Corporation (V:GENX) — Market Cap & Net Worth
Market Cap & Net Worth: GenixPharmaceucticals Corporation (GENX)
GenixPharmaceucticals Corporation (V:GENX) has a market capitalization of $885.77K (CA$1.22 Million) as of September 16, 2026. Listed on the V stock exchange, this Canada-based company holds position #30775 globally and #1598 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GenixPharmaceucticals Corporation's stock price CA$0.02 by its total outstanding shares 61224131 (61.22 Million). Also see GenixPharmaceucticals Corporation total assets for a full breakdown of the balance sheet.
GenixPharmaceucticals Corporation Market Cap History: 2015 to 2026
GenixPharmaceucticals Corporation's market capitalization history from 2015 to 2026. Data shows change from $2.21 Million to $885.77K (-6.20% CAGR). Also see cash flow conversion of GenixPharmaceucticals Corporation for how efficiently the company converts equity into cash flow.
GenixPharmaceucticals Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GenixPharmaceucticals Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GenixPharmaceucticals Corporation (GENX) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
601.30x
GenixPharmaceucticals Corporation's market cap is 601.30 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.55 Million | $924.70K | -$129.05K | 1.68x | N/A |
| 2017 | $4.43 Million | $1.01 Million | -$243.21K | 4.38x | N/A |
| 2018 | $2.44 Million | $419.96K | $134.07K | 5.80x | 18.17x |
| 2019 | $3.10 Million | $137.40K | -$164.70K | 22.56x | N/A |
| 2023 | $885.77K | $12.35K | -$4.40 Million | 71.74x | N/A |
| 2024 | $2.44 Million | $4.05K | -$73.20K | 601.30x | N/A |
Competitor Companies of GENX by Market Capitalization
Companies near GenixPharmaceucticals Corporation in the global market cap rankings as of September 16, 2026. Review GENX intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GenixPharmaceucticals Corporation by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
GenixPharmaceucticals Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, GenixPharmaceucticals Corporation's market cap moved from $2.21 Million to $ 885.77K, with a yearly change of -6.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$885.77K | -33.33% |
| 2025 | CA$1.33 Million | -45.45% |
| 2024 | CA$2.44 Million | +175.00% |
| 2023 | CA$885.77K | -73.33% |
| 2022 | CA$3.32 Million | -34.78% |
| 2021 | CA$5.09 Million | -32.35% |
| 2020 | CA$7.53 Million | +142.86% |
| 2019 | CA$3.10 Million | +27.27% |
| 2018 | CA$2.44 Million | -45.00% |
| 2017 | CA$4.43 Million | +185.71% |
| 2016 | CA$1.55 Million | -30.00% |
| 2015 | CA$2.21 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of GenixPharmaceucticals Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $885.77K USD |
| MoneyControl | $885.77K USD |
| MarketWatch | $885.77K USD |
| marketcap.company | $885.77K USD |
| Reuters | $885.77K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral,… Read more